The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
Open accessAbstract
mAbs to receptor tyrosine kinases such as EGF receptor/ErbB-1 and HER2/ErbB-2 inhibit the tumorigenic growth of certain cancer cells, but although recombinant versions of such Abs are already used in oncology wards, the mechanism underlying immunotherapy remains unknown. We report that anti-EGF receptor Abs promote a slow endocytic process distinct from the rapid EGF-induced receptor internalization. Combining mAbs that engage distinct epitopes significantly accelerates receptor degradation. In addition, mAb combinations are more effective than single Abs in inhibiting HER2 signaling in vitro and tumorigenesis in animals. We present a model attributing efficacy of immunotherapy to the size of Ab-receptor lattices formed at the cell surface, which dictates the rate of endocytic clearance and extent of signaling blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Induction of mutant dynamin specifically blocks endocytic coated vesicle formation.
Damke, H., Baba, T., Warnock, D. E., & Schmid, S. L. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.4.915 · Cited by 1,204
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202132 · Cited by 386
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases
Marmor, M. D., & Yarden, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207390 · Cited by 383
Self-citationKlapper, L. N., Waterman, H., Sela, M., & Yarden, Y. (2000) · PubMed · Cited by 351
Self-citationWaterman, H., Katz, M., Rubin, C., Shtiegman, K., Lavi, S., Elson, A., Jovin, T., & Yarden, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/21.3.303 · Cited by 286
Self-citationFan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., SATO, G. H., & Mendelsohn, J. (1984) · PubMed · Cited by 254
Aboud-Pirak, E., Hurwitz, E., Pirak, M., Bellot, F., Schlessinger, J., & Sela, M. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.20.1605 · Cited by 231
Self-citationStancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., & Sela, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8691 · Cited by 203
Self-citationSpiridon, C., Ghetie, M.-A., Uhr, J. W., Marcheş, R., Li, J. L., Shen, G. L., & Vitetta, E. S. (2002) · PubMed · Cited by 179
Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., & Sela, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201029 · Cited by 174
Self-citationMonoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene
Drebin, J. A., Stern, D. F., Link, V. C., Weinberg, R. A., & Greene, M. I. (1984) · Nature · doi:10.1038/312545a0 · Cited by 163
Kasprzyk, P. G., Song, S. U., Fiore, P. P. D., & King, C. R. (1992) · PubMed · Cited by 151
Hurwitz, E., Stancovski, I., Sela, M., & Yarden, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3353 · Cited by 148
Self-citationJohansen, F. E., & Prywes, R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.9.5920 · Cited by 140
Yamabhai, M., & Anderson, R. G. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200277200 · Cited by 116
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
Harwerth, I. M., Wels, W. S., Schlegel, J., Müller, M., & Ne, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.494 · Cited by 114
Bacus, S. S., Gudkov, A. V., Zelnick, C. R., Chin, D., Stern, R. K., Stancovski, I., Peles, E., Ben-Baruch, N. E., Farbstein, H., & Lupu, R. (1993) · PubMed · Cited by 106
Self-citationXu, F., Lupu, R., Rodriguez, G. C., Whitaker, R. S., Boente, M. P., Berchuck, A., Yu, Y., DeSombre, K., Boyer, C. M., & Bast, R. C. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530310 · Cited by 64
Drebin, J. A., Link, V. C., & Greene, M. I. (1988) · PubMed · Cited by 53
Cited by
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Self-citationEmerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,469
Derailed endocytosis: an emerging feature of cancer
Mosesson, Y., Mills, G. B., & Yarden, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2521 · Cited by 718
Self-citationExploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Metadata
- Authors
- Friedman, L. M., Rinon, A., Schechter, B., Lyass, L., Lavi, S., Bacus, S. S., Sela, M., & Yarden, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-01-31
- Volume
- 102
- Issue
- 6
- Pages
- 1915-1920
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1968961303
- Cited by
- 252
- References
- 27
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.